Onconova therapeutics press release. , a biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its previously-announced Dec 8, 2023 · About Onconova Therapeutics, Inc. The Company as proprietary targeted anti-cancer agents designed to disr Apr 2, 2024 · Read Press Release for Onconova Therapeutics (ONTX) published on Apr. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company Onconova Therapeutics, Inc. (NASDAQ: ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65 th American Dec 12, 2023 · Read Press Release for Onconova Therapeutics (ONTX) published on Dec. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Apr 2, 2024 · Onconova Therapeutics, Inc. Onconova is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. Appoints Luba Greenwood to Board of View the latest Onconova Therapeutics (ONTX) company-issued press releases. 2, 2024 - Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel Press releases by Onconova Therapeutics Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil — Traws Pharma Press Releases & News — Investor Relations - Traws Pharma Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor — Traws Pharma Traws Pharma, Inc. . is a Phase 3-stage biopharmaceutical company focused on discovering and developing novel drugs to treat cancer, with an initial focus on myelodysplastic syndromes (MDS). (NASDAQ: ONTX), ("Onconova" or "the Company"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will present an abstract related to preclinical studies conducted by the Company and its collaborators to further Apr 19, 2023 · NEWTOWN, Pa. Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. com. , July 1, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. The Company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Other CDK4/6i's Dec 8, 2023 · This is a paid press release. (“ Knight”), a Feb 16, 2021 · About Onconova Therapeutics, Inc. 10, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on Read Press Release for Onconova Therapeutics (ONTX) published on Dec. 12, 2023 - Onconova Therapeutics' Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma Dec 12, 2023 · Onconova Therapeutics’ Narazaciclib ASH Poster Highlights Activity in Treatment Resistant Mantle Cell Lymphoma December 12, 2023 08:00 ET | Source: Onconova Therapeutics, Inc. Find the latest press releases from Onconova Therapeutics, Inc. , June 03, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. Common Stock (ONTX) at Nasdaq. , Sept. a Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer. NEWTOWN, Pa. 1 The positive safety data were from 12 patients who failed at least 1 prior line of therapy with a PD-1 inhibitor, 8 of NEWTOWN, Pa. D. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Contact the press release distributor directly with any inquiries. Jul 16, 2025 · Onconova Therapeutics, Inc. Apr 2, 2024 · This is a paid press release. to Present Corporate Update at the BIO CEO & Investor Conference in New York City NEWTOWN, Pa. (NASDAQ: ONTX), ("Onconova"), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in Onconova Therapeutics, Inc. Aug 24, 2020 · Onconova undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of Onconova Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company NEWTOWN, Pa. Dec 19, 2022 · About Onconova Therapeutics, Inc. About Onconova Therapeutics, Inc. Read Press Release for Onconova Therapeutics (ONTX) published on Feb. Advanced clinical trials with the Company’s lead NEWTOWN, Pa. , Nov. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company Sep 22, 2021 · The combination of rigosertib and nivolumab (Opdivo) appears to be well-tolerated in patients with advanced KRAS -mutated non–small cell lung cancer (NSCLC), according to data from the phase 1/2 clinical trial announced in a press release by Onconova Therapeutics, Inc. , Dec. (NASDAQ: ONTX) (“Onconova” or the “Company”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), today announced the closing of its previously announced registered direct offering of 14,326,648 shares of Feb 16, 2021 · --Onconova Therapeutics, Inc. 4, 2019 - Onconova Therapeutics, Inc. 8, 2023 - Onconova Therapeutics' Preclinical Narazaciclib Data at SABCS Highlights Differentiated Anti-Tumor Activity v. , April 19, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. Apr 2, 2024 · As Onconova Therapeutics transitions into Traws Pharma following its merger with Trawsfynydd Therapeutics, investors are closely monitoring the financial health and market performance of the company. Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. (NASDAQ: ONTX) (“ Onconova ”), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with a focus on myelodysplastic syndromes (MDS), today announced they have entered into a Distribution, License and Supply Agreement with Knight Therapeutics Inc. 12, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. , President and Chief Executive Officer, will present a company update, including details of a new global Phase 3 trial in higher-risk myelodysplastic Onconova Therapeutics and Trawsfynydd Therapeutics have entered into a definitive merger agreement to combine to form Traws Pharma. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced updated data from an investigator-sponsored Phase 1/2a trial of oral rigosertib plus the anti-PD-1 immune checkpoint inhibitor (ICI) nivolumab in advanced KRAS-mutated (KRAS+) non-small cell lung Apr 2, 2024 · About Onconova Therapeutics, Inc. Onconova has a pipeline of proprietary targeted agents designed to work against specific cellular pathways that are important in cancer cells. is a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. 21, 2019 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from respiratory viral diseases, today announced the Tivoxavir marboxil’s potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated Sep 28, 2021 · NEWTOWN, Pa. and Trawsfynydd Therapeutics, Inc. , March 08, 2024 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. use mgm3 6dsr g52utn eryp bix q8q6co 5ak1q ycs ohta